FMP
Theratechnologies Inc.
THTX
NASDAQ
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
1.7 USD
-0.07 (-4.12%)
Mr. Paul Lévesque
Healthcare
Drug Manufacturers - Specialty & Generic
NASDAQ
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
0001512717
CA88338H7040
88338H100
2015 Peel Street
15143367800
CA
103
Feb 13, 2009
Mr. Jocelyn Lafond L.L.M., LL.B.
General Counsel & Corporate Secretary
316.29k
1968
Mr. John Leasure
Global Commercial Officer
420.91k
1965
Mr. Paul Lévesque
President, Chief Executive Officer & Dir...
1.18M
1964
Hon. Andre Dupras M.Sc.
Vice President of Human Resources
0
1964
Mr. Philippe Dubuc M.B.A., MBA
Senior Vice President & Chief Financial ...
432.31k
1967
Dr. Christian Marsolais Ph.D.
Senior Vice President & Chief Medical Of...
434.61k
1963
As of December 31, 2024, the total employee count stands at 103, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.